Skip to content
Business Company News, Medical Health Aged Care

Professor Peter van Wijngaarden to become next Director and CEO of The Florey

The Florey 2 mins read

The Florey Board appoints new Director and CEO  

After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. 

Board Chair Mr Martin Adams said Professor van Wijngaarden is an outstanding leader and an experienced clinician researcher who will take The Florey’s work to the world stage. 

“On behalf of the Board, I warmly welcome Peter to The Florey. As the largest brain research centre in the Southern Hemisphere, The Florey is home to remarkably talented people committed to advancing neuroscience and mental health research. Peter is exceptionally well-placed to take The Florey’s impact to the next level.” 

Professor van Wijngaarden said he was looking forward to taking up his new role next month. 

“I am honoured to be joining The Florey as its new Director and excited to be working with scientists who are leading the world in making fundamental discoveries in neuroscience and improving diagnostics and treatments for an impressive range of mental health and brain-related conditions,” Professor van Wijngaarden said.  

“The Florey has an incredible reputation and I look forward to building on that impressive legacy,” he said. 

Mr Adams thanked retiring Director Professor Trevor Kilpatrick for his leadership and commitment to the organisation.  

"Trevor has done an outstanding job leading The Florey through a period of important structural changes which have positioned us to continue to make significant scientific breakthroughs with our partners. I’m confident that Peter will build upon these efforts.”  

Professor Kilpatrick said he was proud to have served The Florey as its sixth Director. 

“I’m delighted that Professor van Wijngaarden has accepted this appointment,” Professor Kilpatrick said.  

“I have known Peter since his return from Cambridge where he undertook research in regenerative neuroscience with my long-term friend and colleague Professor Robin Franklin. 

“Since then, Peter has had a stellar career as a clinician scientist, administrator and entrepreneur. He is ideally placed to lead The Florey in the next phase of its journey as a world-leading neuroscience and mental health-oriented research institute.” 

Peter is Professor of Ophthalmology at the University of Melbourne and has served as Deputy Director at the Centre for Eye Research Australia (CERA). 

His research interests include retinal imaging, artificial intelligence, multiple sclerosis and Alzheimer’s disease. 

 


Key Facts:
  • Professor Peter van Wijngaarden has been selected to lead The Florey from 1 August 2024 

  • Professor van Wijngaarden is currently Deputy Director of the Centre for Eye Research Australia 


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere.

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley, Media and Communications Manager

[email protected] | 0456 666 271

Media

More from this category

  • Business Company News, Oil Mining Resources
  • 17/12/2025
  • 13:15
RocketDNA (ASX:RKT)

RocketDNA Receives ~A$1M in New Orders

HIGHLIGHTS New 12-month order fromBHP WAIO for dual xBot deployment Contract renewal and expansion atAssmang’s Khumani Iron Ore Mine, including a 12-month drone services extension and an additional 12-month xBot program Additional xBot units ordered by Norton Gold Fields Aggregate value of new binding contracts and purchase orders received of approximately A$1.0 million 17 December 2025, RocketDNA Ltd (ASX: RKT) (RocketDNA or the Company), a technology services company specialising in AI-powered drone data solutions, has received approximately A$1M in new purchase orders from existing customers, relating to the expansion of existing autonomous drone programs. These orders reflect increasing demand for…

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTAN® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.